Diviner technology is the first-in-class small molecule inhibitor (SD133) of a novel cancer target (CDH11) increases survival of animals with pancreatic cancer.
Drug Development
Animal challenging, early ADME-T, and PK/PD studies are completed. Advanced preclinical studies are in progress. Diviner technology is funded by the NIH, DoD, NIH SBIR awards and Company partnerships.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.
